Regeneron announced that it has entered into a global collaboration agreement with Tessera Therapeutics to commercialize and ...

Eli Lilly has announced a price reduction for Zepbound single-dose vials, targeting improved affordability for self-pay ...

New data shows that China and the US dominate breast cancer clinical trial expertise while lower-income countries remain ...

Many PBMs are also finding their business at risk as pharma–PBM tension continues to intensify. We predict that this tension will continue in 2026, especially for companies with late-stage assets in ...

Along with the deployment and integration the new agentic AI tool, FDA is also launching an agentic AI challenge for its ...

Patient-centric evidence, such as PROs and RWE, offers insights into patients' needs, enhancing drug development beyond traditional endpoints. Challenges include increased complexity and regulatory ...